Biopharma hedge funds turned in generally weak performances in February.
After a fairly strong January, most of the funds lost money for the month, and this pushed several of the funds back into the red for the year.
Sharp monthly swings are common among biopharma hedge funds, since many of their holdings are fledgling companies that are trying to develop their initial drugs.
